View Older Stories

Mar 16, 2026 11:22AM H.C. Wainwright Reiterates Buy Rating on Savara (SVRA): 'well positioned ahead of the August PDUFA date'

Mar 13, 2026 08:06AM Savara submits BLA for MOLBREEVI with FDA priority review set for August

Mar 6, 2026 04:05PM Savara receives FDA day 74 letter, submits European filing for MOLBREEVI

Feb 23, 2026 04:58AM Savara (SVRA) Reiterated at Market Outperform by Citizens Ahead of March Conference

Feb 20, 2026 04:15PM FDA files Savara's MOLBREEVI application for rare lung disease

Jan 27, 2026 08:06AM Savara amends Hercules Capital debt facility for $75M upon FDA approval

Dec 23, 2025 06:46AM Guggenheim Reiterates Buy Rating on Savara (SVRA)

Dec 23, 2025 06:42AM Savara (SVRA) PT Raised to $10 at H.C. Wainwright

Dec 22, 2025 08:31AM Savara resubmits drug application to FDA with new manufacturer

Dec 11, 2025 08:05AM Savara receives European patent intent for MOLBREEVI formulation

Dec 8, 2025 07:32AM Piper Sandler on Biotechnology: 'What Commercial Names to Own in 2026?'

Dec 2, 2025 08:06AM Savara and PARI receive European patent for drug-device combination

Nov 13, 2025 06:36AM Savara (SVRA) Misses Q3 EPS by 1c

Nov 13, 2025 04:15AM Savara (SVRA) PT Lowered to $10 at Citizens on More Potentially Dilutive Shares

Oct 29, 2025 04:01PM Savara secures $75 million funding from RTW for drug launch

Oct 23, 2025 04:25AM Savara (SVRA) PT Raised to $11 at Citizens on Molbreevi Demand Prospects

Sep 9, 2025 06:56AM Savara (SVRA) PT Raised to $11 at Guggenheim

Sep 4, 2025 06:41AM Savara (SVRA) PT Raised to $8 at H.C. Wainwright

Sep 2, 2025 09:01AM Savara finds 50% more autoimmune PAP patients in US claims data study

Aug 21, 2025 04:11AM Citizens JMP Reiterates Market Outperform Rating on Savara (SVRA)

Aug 15, 2025 08:58AM H.C. Wainwright Upgrades Savara (SVRA) to Buy

Aug 15, 2025 08:14AM Savara (SVRA) PT Raised to $6 at Oppenheimer

Aug 13, 2025 07:02PM Savara (SVRA) Misses Q2 EPS by 2c

Jun 5, 2025 11:58AM SVRA ALERT: Savara Inc. Investigated For Possible Securities Fraud; Investors Who Lost Money Should Contact Block & Leviton To Potentially Recover Losses

Jun 2, 2025 08:58AM Oppenheimer Assumes Savara (SVRA) at Outperform (correction)

May 29, 2025 06:07AM H.C. Wainwright Downgrades Savara (SVRA) to Neutral

May 28, 2025 07:09AM Savara (SVRA) PT Lowered to $8 at Guggenheim

May 28, 2025 07:07AM Savara (SVRA) PT Lowered to $2 at Evercore ISI

May 27, 2025 08:06AM Savara (SVRA) Receives Refusal to File (RTF) Letter From FDA for BLA for MOLBREEVI

May 13, 2025 04:19PM Savara (SVRA) Misses Q1 EPS by 2c

Apr 23, 2025 04:28AM Citizens JMP Reiterates Market Outperform Rating on Savara (SVRA)

Apr 11, 2025 09:44AM Piper Sandler: 'What Biotech Names to Own in Market Volatility'

Apr 7, 2025 04:05PM Savara (SVRA) Announces Encore Presentations From the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution

Mar 28, 2025 06:42AM H.C. Wainwright Reiterates Buy Rating on Savara (SVRA)

Mar 27, 2025 04:55AM Citizens JMP Reiterates Market Outperform Rating on Savara (SVRA)

Mar 26, 2025 04:46PM Savara (SVRA) Enters Into Non-Dilutive Debt Financing for up to $200M With Hercules Capital (HTGC)

Mar 26, 2025 04:05PM Savara (SVRA) Completes Submission of the BLA for MOLBREEVI

Mar 6, 2025 08:07AM Savara (SVRA) Announces U.S. Launch of the aPAP ClearPath Dried Blood Spot Test

Jan 30, 2025 08:39AM Savara (SVRA) Announces Manuscript on Long-Term Outcomes With Molgramostim Inhalation Solution

Dec 18, 2024 04:07PM Savara (SVRA) Initiates Rolling Submission of BLA to FDA for MOLBREEVI for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis

Nov 13, 2024 06:54AM Savara (SVRA) PT Lowered to $6 at H.C. Wainwright

Nov 13, 2024 06:09AM Evercore ISI Downgrades Savara (SVRA) to In Line

Nov 12, 2024 08:10AM Savara (SVRA) Reports In-Line Q3 EPS

Nov 12, 2024 08:10AM Savara (SVRA) Reports In-Line Q3 EPS

Oct 10, 2024 07:42AM Piper Sandler Reiterates Overweight Rating on Savara (SVRA)

Oct 8, 2024 06:48AM H.C. Wainwright Reiterates Buy Rating on Savara (SVRA)

Oct 3, 2024 07:19AM Piper Sandler Reiterates Overweight Rating on Savara (SVRA)

Oct 1, 2024 07:03AM H.C. Wainwright Reiterates Buy Rating on Savara (SVRA)

Sep 30, 2024 03:32PM Oppenheimer Reiterates Outperform Rating on Savara (SVRA)

Sep 27, 2024 08:05AM Savara (SVRA) Announces Expanded Access Program for Molgramostim Inhalation Solution for Patients with Autoimmune Pulmonary Alveolar Proteinosis

View Older Stories